Literature DB >> 9155703

Leu-M1 immunoreactivity and phaeochromocytoma.

L Masmiquel1, M Castro-Forns, I de Torres, A García, M T Vidal, R Simó.   

Abstract

The aim was to evaluate Leu-M1 immunoreactivity as a prognostic factor in phaeochromocytoma. Anti-Leu-M1 monoclonal antibodies were used to determine the Leu-M1 immunoreactivity in 17 histologically confirmed phaeochromocytomas from 15 patients, using an avidin-biotin technique. Ten patients had a sporadic phaeochromocytoma, and five had multiple endocrine neoplasia type 2A (MEN 2A). Malignancy was diagnosed in three patients by the presence of metastases. Leu-M1 immunoreactivity was shown in 12 (70.5%) phaeochromocytomas. Three patterns of arrangement were observed: isolated (scattered positive cells) (n = 3); focal (aggregates of positive cells) (n = 5), and diffuse patterns (dispersed positive cells) (n = 4). Two cases of malignant phaeochromocytoma were positive (one focal and one isolated pattern). All cases of MEN 2A showed immunoreactivity, although no characteristic pattern was prevalent. A diffuse pattern was observed in all phaeochromocytomas longer than 7 cm. In conclusion, Leu-M1 expression is frequent in phaeochromocytoma. However, Leu-M1 immunoreactivity seems to be useless in predicting malignant behaviour and to be influenced mainly by tumour size.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155703      PMCID: PMC499747          DOI: 10.1136/jcp.50.2.168

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern.

Authors:  O Nativ; C S Grant; S G Sheps; J R O'Fallon; G M Farrow; J A van Heerden; M M Lieber
Journal:  J Surg Oncol       Date:  1992-08       Impact factor: 3.454

2.  The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma.

Authors:  O Nativ; C S Grant; S G Sheps; J R O'Fallon; G M Farrow; J A van Heerden; M M Lieber
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

3.  Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; T Löning; W Böcker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases.

Authors:  K Sheibani; H Battifora; J S Burke; H Rappaport
Journal:  Am J Surg Pathol       Date:  1986-04       Impact factor: 6.394

Review 5.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

Authors:  E L Bravo
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

6.  Leu-M1--a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues.

Authors:  G S Pinkus; P Thomas; J W Said
Journal:  Am J Pathol       Date:  1985-05       Impact factor: 4.307

7.  Prognostic factors in medullary thyroid carcinomas.

Authors:  S Schröder; H Dralle
Journal:  Horm Metab Res Suppl       Date:  1989

8.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.

Authors:  H P Neumann; D P Berger; G Sigmund; U Blum; D Schmidt; R J Parmer; B Volk; G Kirste
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

  8 in total
  1 in total

Review 1.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.